Master S Wealth Management Inc. Acquires Shares of 16,467 Kenvue Inc. $KVUE

Master S Wealth Management Inc. acquired a new stake in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 16,467 shares of the company’s stock, valued at approximately $345,000. Kenvue comprises 0.2% of Master S Wealth Management Inc.’s holdings, making the stock its 28th biggest position.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pittenger & Anderson Inc. purchased a new stake in Kenvue in the first quarter valued at approximately $30,000. TruNorth Capital Management LLC purchased a new stake in Kenvue in the first quarter valued at approximately $36,000. Truvestments Capital LLC purchased a new stake in Kenvue in the first quarter valued at approximately $37,000. Trust Co. of Vermont lifted its stake in Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $14.05 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $25.17. The stock has a market cap of $26.96 billion, a PE ratio of 18.99, a price-to-earnings-growth ratio of 2.34 and a beta of 0.72. The firm’s fifty day simple moving average is $18.66 and its 200-day simple moving average is $21.12.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same period in the prior year, the company posted $0.32 EPS. The business’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.9%. Kenvue’s dividend payout ratio is currently 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several analyst reports. Rothschild Redb upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Bank of America dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, October 8th. Redburn Partners set a $22.00 price objective on shares of Kenvue in a research note on Friday, September 26th. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Royal Bank Of Canada dropped their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus target price of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.